Gary R. Hudes
- Pulmonary and Respiratory Medicine top 0.1%
- Molecular Biology top 0.5%
- Cancer Research top 0.2%
- Oncology top 0.5%
- Surgery top 2%
- Co-authors
- Robert J. MotzerRobert A. FiglinGeorge WildingBrian I. RiniM. Dror MichaelsonBruce G. RedmanDaniel J. GeorgeMichael A. Carducci
- Topics
- Renal cell carcinoma treatment (39 papers)Renal and related cancers (23 papers)Prostate Cancer Treatment and Research (22 papers)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Gary R. Hudes
101 papers receiving 10.5k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Pulmonary and Respiratory Medicine 6.8k
- Molecular Biology 6.1k
- Cancer Research 3.6k
- Oncology 3.5k
- Surgery 1.2k
Countries citing papers authored by Gary R. Hudes
This map shows the geographic impact of Gary R. Hudes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary R. Hudes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary R. Hudes more than expected).
Fields of papers citing papers by Gary R. Hudes
This network shows the impact of papers produced by Gary R. Hudes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary R. Hudes. The network helps show where Gary R. Hudes may publish in the future.
Co-authorship network of co-authors of Gary R. Hudes
This figure shows the co-authorship network connecting the top 25 collaborators of Gary R. Hudes. A scholar is included among the top collaborators of Gary R. Hudes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary R. Hudes. Gary R. Hudes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 26 | |
| 2 | 56 | |
| 3 | 141 | |
| 4 | 34 | |
| 5 | 53 | |
| 6 | 54 | |
| 7 | 83 | |
| 8 | 78 | |
| 9 | 35 | |
| 10 | 56 | |
| 11 | 82 | |
| 12 | Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches | 4 |
| 13 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinomabreakdown → | 1304 |
| 14 | 150 | |
| 15 | 8 | |
| 16 | 14 | |
| 17 | 23 | |
| 18 | 20 | |
| 19 | 42 | |
| 20 | 5 |
About Gary R. Hudes
Gary R. Hudes is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology, having authored 102 papers that have together received 10.7k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (39 papers), Renal and related cancers (23 papers) and Prostate Cancer Treatment and Research (22 papers). The work is most often cited by research in Cancer Research (3.6k citations), Pulmonary and Respiratory Medicine (6.8k citations) and Oncology (3.5k citations). Gary R. Hudes has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Robert J. Motzer, Robert A. Figlin, George Wilding, Brian I. Rini, M. Dror Michaelson, Bruce G. Redman, Daniel J. George, Michael A. Carducci, Sindy T. Kim and Laurence Moore. Their work appears in journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.